KRYS
Price:
$184.19
Market Cap:
$5.29B
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syn...[Read more]
Industry
Biotechnology
IPO Date
2017-09-20
Stock Exchange
NASDAQ
Ticker
KRYS
According to Krystal Biotech, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 46.75. This represents a change of -87.78% compared to the average of 382.66 of the last 4 quarters.
The mean historical PE Ratio of Krystal Biotech, Inc. over the last ten years is 15.27. The current 46.75 PE Ratio has changed 30.51% with respect to the historical average. Over the past ten years (40 quarters), KRYS's PE Ratio was at its highest in in the March 2024 quarter at 1.34K. The PE Ratio was at its lowest in in the December 2019 quarter at -44.82.
Average
15.27
Median
-21.85
Minimum
-46.13
Maximum
308.15
Discovering the peaks and valleys of Krystal Biotech, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 200.26%
Maximum Annual PE Ratio = 308.15
Minimum Annual Increase = -2235.92%
Minimum Annual PE Ratio = -46.13
Year | PE Ratio | Change |
---|---|---|
2023 | 308.15 | -2235.92% |
2022 | -14.43 | -35.36% |
2021 | -22.32 | -36.31% |
2020 | -35.04 | -24.04% |
2019 | -46.13 | 115.79% |
2018 | -21.38 | 200.26% |
2017 | -7.12 | -82.00% |
The current PE Ratio of Krystal Biotech, Inc. (KRYS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
90.47
5-year avg
38.05
10-year avg
15.27
Krystal Biotech, Inc.’s PE Ratio is greater than MeiraGTx Holdings plc (-2.68), greater than Apellis Pharmaceuticals, Inc. (-15.28), greater than Deciphera Pharmaceuticals, Inc. (-11.74), greater than REGENXBIO Inc. (-2.41), greater than Rhythm Pharmaceuticals, Inc. (-11.58),
Company | PE Ratio | Market cap |
---|---|---|
-2.68 | $300.31M | |
-15.28 | $5.00B | |
-11.74 | $2.21B | |
-2.41 | $567.38M | |
-11.58 | $3.01B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Krystal Biotech, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Krystal Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Krystal Biotech, Inc.'s PE Ratio?
How is the PE Ratio calculated for Krystal Biotech, Inc. (KRYS)?
What is the highest PE Ratio for Krystal Biotech, Inc. (KRYS)?
What is the 3-year average PE Ratio for Krystal Biotech, Inc. (KRYS)?
What is the 5-year average PE Ratio for Krystal Biotech, Inc. (KRYS)?
How does the current PE Ratio for Krystal Biotech, Inc. (KRYS) compare to its historical average?